Click here for slides on this topic


Glimepiride

A type of oral antihyperglycemic agent of the sulfonylurea class that stimulates insulin secretion from the pancreatic beta-cells. It is indicated as an adjunct to diet and exercise to lower blood glucose levels among patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone. Refer to full prescribing information.
The following content matched the glossary term: Glimepiride

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

American Diabetes Association (ADA) Nutrition Guidelines for Adults With Diabetes

Top

Diabetes management guidelines for nutrition from the American Diabetes Association (ADA)

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 - Studies Question Sulfonylurea Safety

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

 

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Clinical Insights in Diabetes Newsletter September 2012

Top

Clinical Insights® in Diabetes newsletter September 2012.

Intensive therapy in ACCORD-BP, Roux-en-Y gastric bypass for type 2 diabetes and obesity, diabetes and CVD mortality, and linagliptin and glimepiride for diabetes treatment.

1 2 3 4 Next 

Slide Library Results

Search Results for: Glimepiride Slides Found: 43
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
Glycemic Control With Addition of Sitagliptin to Glimepiride and/or Metformin
Effect of Vildagliptin Added to Glimepiride on ß-Cell Function in Patients With Type 2 Diabetes
EUREXA Trial: Change in Body Weight
EUREXA Trial: Hypoglycemia and Adverse Events
EUREXA Trial: Attainment of A1C <7.0% and ≤6.5%
EUREXA Trial: Primary Outcome—Time to Treatment Failure
EUREXA Trial: Design and Enrollment Profile
EUREXA Trial: Design
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Design
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Change in A1C from Baseline
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Secondary Endpoints
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: CV Safety, Glucose, Adverse Events
Liraglutide 12-Week Treatment: Effect on Glycemic Control
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in Patients With Type 2 Diabetes
Liraglutide Reduces A1C Irrespective of Baseline A1C
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Body Weight in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Fasting Plasma
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
Insulin Sulfonlyrea Added to Metformin CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality Design | NDEI
HARMONY 3 Albiglutide A1C Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide FPG Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Weight Loss Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide Type 2 Diabetes Metformin | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
AWARD-2: Once-Weekly Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
Lower A1C With Dulaglutide Vs Insulin Glargine AWARD-2 Results | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
AWARD-2 Design Dulaglutide Vs Insulin Glargine Type 2 Diabetes | PPT
AWARD-2: Lower A1C With Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
AWARD-2 Similar Adverse Events With Dulaglutide & Insulin Glargine Type 2 Diabetes | NDEI